Email this article Epidermodysplasia verruciformis (EV)
Abstract
Epidermodysplasia verruciformis (EV) is an uncommon genetic skin condition characterized by a high vulnerability to specific types of human papillomavirus (HPV), increasing the likelihood of non-melanoma skin cancer. The disorder is inherited in an autosomal recessive pattern, and certain families exhibit mutations in the TMC6 or TMC8 genes situated on chromosome 17q25.3. During childhood, individuals with EV frequently develop flat-topped, papular lesions that resemble verrucae planae on their limbs, reddish-brown plaques, or lesions resembling pityriasis versicolor on their neck, trunk, and face. In addition, around two-thirds of patients may experience actinic keratoses and cutaneous malignancies during their twenties or thirties. Diagnosis of EV involves a skin biopsy to examine histological characteristics and detect HPV presence in a skin lesion.
Additionally, there is an acquired form of EV observed in individuals with weakened immune systems. Although no definitive treatments exist for EV, patients are advised to rigorously practice sun protection measures to reduce the risk of developing non-melanoma skin cancer. Regular skin examinations throughout a patient's lifetime are also recommended to detect precancerous skin lesions and early-stage cancer.
Keywords
References
Pfister H. Human papillomaviruses and skin cancer. Semin Cancer Biol. 1992 Oct;3(5):263–71.
Orth G. Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: guilty or innocent. J Invest Dermatol. 2005;125(1):98–107.
Majewski S, Jablonska S. Why epidermodysplasia verruciformis–a rare genetic disease–has raised such great interest. Int J Dermatol. 2004;43(4):309–11.
Alshammari R, Al-Issa A, Ghobara YA. Epidermodysplasia Verruciformis: A Rare. 2020;
McLaughlin-Drubin ME. Human papillomaviruses and non-melanoma skin cancer. In: Seminars in oncology. Elsevier; 2015. p. 284–90.
Horton JS, Stokes AJ. The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma. Oncoimmunology. 2014;3(4):e28288.
Liu-Smith F, Jia J, Zheng Y. UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer. Ultrav Light Hum Heal Dis Environ. 2017;27–40.
De Jong SJ, Imahorn E, Itin P, Uitto J, Orth G, Jouanguy E, et al. Epidermodysplasia verruciformis: inborn errors of immunity to human beta-papillomaviruses. Front Microbiol. 2018;9:1222.
Ramoz N, Rueda L-A, Bouadjar B, Montoya L-S, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet. 2002;32(4):579–81.
Orth G. Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. In: Seminars in immunology. Elsevier; 2006. p. 362–74.
Foong HBB, Ibrahimi OA, Elpern DJ, Tyring S, Rady P, Carlson JA. Multiple facial seborrheic keratosis‐like lesions in a young woman with epidermodysplasia verruciformis. Int J Dermatol. 2008;47(5):476–8.
Sá NB de, Guerini MB, Barbato MT, Giunta G Di, Nunes DH. Epidermodysplasia verruciformis: clinical presentation with varied forms of lesions. An Bras Dermatol. 2011;86:57–60.
Androphy EJ, Dvoretzky I, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis: genetic and virologic studies of a kindred. Arch Dermatol. 1985;121(7):864–8.
McDermott DF, Gammon B, Snijders PJ, Mbata I, Phifer B, Howland Hartley A, et al. Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol. 2009;26(3):306–10.
Li S, Duo L, Wang H, Dai W, Zhou E, Xu Y, et al. Identification of LCK mutation in a family with atypical epidermodysplasia verruciformis with T‐cell defects and virus‐induced squamous cell carcinoma. Br J Dermatol. 2016;175(6):1204–9.
De Jong SJ, Créquer A, Matos I, Hum D, Gunasekharan V, Lorenzo L, et al. The human CIB1–EVER1–EVER2 complex governs keratinocyte-intrinsic immunity to β-papillomaviruses. J Exp Med. 2018;215(9):2289–310.
Przybyszewska J, Zlotogorski A, Ramot Y. Re-evaluation of epidermodysplasia verruciformis: Reconciling more than 90 years of debate. J Am Acad Dermatol. 2017;76(6):1161–75.
Meyers JM, Grace M, Uberoi A, Lambert PF, Munger K. Inhibition of TGF-β and NOTCH signaling by cutaneous papillomaviruses. Front Microbiol. 2018;9:389.
Olczak P, Wong M, Tsai H-L, Wang H, Kirnbauer R, Griffith AJ, et al. Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice. Virology. 2022;575:63–73.
Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010;40:1–13.
Akgül B, Lemme W, Garcia-Escudero R, Storey A, Pfister HJ. UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes. Arch Virol. 2005;150:145–51.
Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445(1–2):21–34.
Pfister H. Biologie der Epidermodysplasia-verruciformis-assoziierten HPV. Der Hautarzt. 2011;62(1):17–21.
Patel T, Morrison LK, Rady P, Tyring S. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers. 2010;29(3–4):199–206.
Mertz KD, Schmid M, Burger B, Itin P, Palmedo G, Schärer L, et al. Detection of Merkel cell polyomavirus in epidermodysplasia-verruciformis-associated skin neoplasms. Dermatology. 2011;222(1):87–92.
Kwon EM, Halvorson CR, Rady P, Tyring S, Nguyen HP, Kao GF, et al. Merkel cell polyomavirus detection in a patient with familial epidermodysplasia verruciformis. Pediatr Dermatol. 2013;30(4):505–7.
Michael KM, Waterboer T, Pfister H, Gariglio M, Majewski S, Favre M, et al. Seroreactivity of 38 Human Papillomavirus Types in Epidermodysplasia Verruciformis Patients, Relatives, and Controls. J Invest Dermatol [Internet]. 2010;130(3):841–8. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X15347424
Saeidian AH, Youssefian L, Naji M, Mahmoudi H, Barnada SM, Huang C, et al. Whole transcriptome–based skin virome profiling in typical epidermodysplasia verruciformis reveals α-, β-, and γ-HPV infections. JCI insight. 2023;8(5).
Bostan E, Akdogan N, Gokoz O. Epidermodysplasia Verruciformis After Hematopoietic Stem Cell Transplantation in a Patient With Severe Combined Immunodeficiency Syndrome. Am J Dermatopathol. 2021;43(5):e65–7.
Moore S, Rady P, Tyring S. Acquired epidermodysplasia verruciformis: clinical presentation and treatment update. Int J Dermatol. 2022;61(11):1325–35.
Limmer AL, Wu JH, Doan HQ, Rady PL, Tyring SK. Acquired epidermodysplasia verruciformis: a 10‐year anniversary update. Br J Dermatol. 2020;182(3):790–2.
Seeborg FO, Saxena K, Nicholas SK, Banerjee PP, Angelo LS, Mace EM, et al. Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency. J Allergy Clin Immunol. 2014;134(6):1451–3.
Abd Hamid IJ, Slatter MA, McKendrick F, Pearce MS, Gennery AR. Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report. Blood, J Am Soc Hematol. 2017;129(15):2198–201.
Burger B, Kind F, Spoerri I, Rütten A, Battegay M, Häusermann P, et al. HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. Aids. 2010;24(17):2758–60.
Burger B, Spörri I, Stegmann DA, De Mesmaker J, Schaub S, Itin PH, et al. Risk of cutaneous squamous cell carcinoma development in renal transplant recipients is independent of TMC/EVER alterations. Dermatology. 2015;231(3):245–52.
Carré D, Dompmartin A, Verneuil L, Verdon R, Comoz F, Le Brun E, et al. Epidermodysplasia verruciformis in a patient with HIV infection: no response to highly active antiretroviral therapy. Int J Dermatol. 2003;42(4):296–300.
Rallis E, Paparizos V, Kyriakis K, Katsambas A. Treatment of epidermodysplasia verruciformis in human immunodeficiency virus-positive patients. J Eur Acad Dermatology Venereol JEADV. 2008;23(2):195–6.
da Cruz Silva LL, de Oliveira WRP, Sotto MN. Epidermodysplasia verruciformis: revision of a model of carcinogenic disease. Surg Exp Pathol [Internet]. 2019;2(1):20. Available from: https://doi.org/10.1186/s42047-019-0046-7
Araújo MG, Magalhães GM, Garcia LC, Vieira ÉC, Carvalho-Leite M de LR de, Guedes ACM. Update on human papillomavirus-Part II: complementary diagnosis, treatment and prophylaxis. An Bras Dermatol. 2021;96:125–38.
Barcelos ACN, Sotto MN. Comparative analysis of the expression of cytokeratins (1, 10, 14, 16, 4), involucrin, filaggrin and E‐cadherin in plane warts and epidermodysplasia verruciformis plane wart‐type lesions. J Cutan Pathol. 2009;36(6):647–54.
Westphal K, Akgül B, Storey A, Nindl I. Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures. Anal Cell Pathol. 2009;31(3):213–26.
Anadolu R, Oskay T, Erdem C, Boyvat A, Terzi E, Gürgey E. Recently, retinoid and interferon therapies have been found to be of value in the treatment of EV. J Am Acad Dermatol [Internet]. 2001;45(2):296–9. Available from: https://www.sciencedirect.com/science/article/pii/S0190962201063708
Janssen K, Lucker GPH, Houwing RH, Van Rijssel R. Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod. Int J Dermatol. 2007;46:45–7.
Berthelot C, Dickerson MC, Rady P, He Q, Niroomand F, Tyring SK, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol. 2007;56(5):882–6.
Karrer S, Szeimies RM, Abels C, Wlotzke U, Stolz W, Landthaler M. Epidermodysplasia verruciformis treated using topical 5‐aminolaevulinic acid photodynamic therapy. Br J Dermatol. 1999;140(5):935–8.
de Oliveira WRP, Neto CF, Rivitti EA. The lack of a clinical effect of cimetidine in the treatment of epidermodysplasia verruciformis. J Am Acad Dermatol. 2004;50(6):e6.
Micali G, Nasca MR, Dall’Oglio F, Musumeci ML. Cimetidine therapy for epidermodysplasia verruciformis. J Am Acad Dermatol. 2003;48(2):S9–10.
de Oliveira WR, da Cruz Silva LL, Festa Neto C, Tyring S. Deleterious effect of radiation therapy on epidermodysplasia verruciformis patients. J Cutan Med Surg. 2015;19(4):416–21.
Rajabi MT, Ghasemi H, Safizadeh M, Jamshidi S, Asadi-Amoli F, Abrishami Y, et al. Conjunctival squamous cell carcinoma with intraocular invasion after radiotherapy in epidermodysplasia verruciformis. Can J Ophthalmol. 2014;49(2):e43–6.
Refbacks
- There are currently no refbacks.
Copyright (c) 2025 Sara Nasiri, Niloofar Faraji, Mahsa Motiei, Sahand Sadat Mansouri
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.